Require insurance coverage of pediatric autoimmune disorders
Summary
LB762 requires most individual and group health insurance policies, hospital/medical/surgical expense policies, and self-funded employee benefit plans to cover treatment for certain pediatric autoimmune neuropsychiatric disorders, to the extent not preempted by federal law. The bill specifically addresses pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS), and defines those conditions in the statute.
Under the bill, covered treatment must be recommended by the patient’s licensed physician and may include antibiotics, medications, behavioral therapies to manage neuropsychiatric symptoms, plasma exchange, and immunoglobulin. The measure is framed as an insurance mandate, meaning it adds a new required benefit for applicable health plans delivered, issued, or renewed in Nebraska after the effective date.
Impact
LB762 amends Nebraska insurance law by creating a new coverage requirement for insurers and certain self-funded employer plans, subject to federal preemption. It expands mandated health benefits for pediatric neuropsychiatric conditions and affects individual and group health insurance carriers, hospital and medical service plans, and some employer-sponsored plans. The bill also adds statutory definitions for PANS and PANDAS to guide coverage determinations and treatment eligibility.
Sentiment
The available voting history suggests broad legislative support for the bill. It advanced with strong majorities and passed final reading 45-4, and the committee amendment was adopted unanimously. No committee transcript is available here, but the vote pattern indicates the measure was generally well received and not highly divisive.
Contention
The main policy issue is the insurance mandate itself: requiring coverage for treatments that may be costly, specialized, or subject to medical debate. Potential points of contention include the scope of covered therapies, the reliance on physician recommendation, and the impact on premiums or plan costs for insurers and self-funded employers. The bill also includes a federal preemption limitation, which may affect how broadly the mandate can be applied to certain employer plans.